EyeFocus Eye Care Innovation Conference

31 January 2017, London, UK.
EyeFocus is holding a one day conference about eye-care innovation to end the second EyeFocus program. The conference is instead of the traditional demo day, and will go beyond startups pitching to investors, instead presenting the ecosystem EyeFocus has built in eye-care innovation.

The conference will bring together thought leaders from across eye-care, innovation, and tech. The day will feature keynote talks, discussion panels, and short pitches from a broad range of the companies in the EyeFocus program, from startups to developed businesses.

The aim of the day is to share the built ecosystem, and the knowledge clustered around EyeFocus, and to promote innovation in eye-care. The day will be a mix of networking, education, and information for people working in eye-care, health tech, and startups.

EyeFocus Eye Care Innovation Conference is sponsored by Bayer, and has partnered with the world famous Royal National Institute for Blind People (RNIB), and Royal Academy of Engineering (RAENG) to bring thought leaders from across the eye-care spectrum together for a unique event in the centre of London.

For further information and to buy tickets, please visit:
https://www.eventbrite.com/e/eyefocus-conference-tickets-29612858858?aff=eHealthNews&afu=197085922377

About EyeFocus
EyeFocus is the world's first eye-care accelerator and innovation program. We run events around the world to bring together opinion leaders and practitioners in eye-care innovation to leave our ecosystem better connected, and to focus academics, innovators, and practitioners on thinking about how to create new products and solutions for people who are blind or visually impaired.

EyeFocus is a project of Newsquare Innovation. Newsquare develops programs to create connected ecosystems in healthcare innovation, accelerating early stage companies, and building bridges between academia, industry, entrepreneurs, and healthcare.

Most Popular Now

BioMotiv and Bristol-Myers Squibb announce the lau…

BioMotiv, a mission-driven drug development accelerator associated with The Harrington Project for discovery and development, that advances breakthrough discoveries from ...

CEPI and GSK announce collaboration to strengthen …

CEPI, the Coalition for Epidemic Preparedness Innovations, and GSK announced a new collaboration aimed at helping the global effort to develop a vaccine for the 2019-nCoV...

Sandoz completes acquisition of Aspen's Japanese o…

Sandoz today announced that it has successfully completed the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen ...

Sanofi brain-penetrant BTK inhibitor meets primary…

The Sanofi Phase 2b study evaluating its investigational BTK (Bruton's tyrosine kinase) inhibitor (SAR442168), an oral, brain-penetrant, selective small molecule, achieve...

Roche reports very strong results in 2019

In 2019, Group sales rose 9% to CHF 61.5 billion and core EPS grew 13%, ahead of sales. The core operating profit increased 11%, reflecting the strong underlying business...

Sanofi completes acquisition of Synthorx, Inc.

Sanofi announced the successful completion of its acquisition of Synthorx, Inc. ("Synthorx") for $68 per share in cash. "The acquisition of Synthorx perfectly aligns w...

Merck donates one billionth praziquantel tablet

Merck, a leading science and technology company, today announced that it has already donated 1 billion tablets of praziquantel, the standard medication for the treatment ...

WHO, China leaders discuss next steps in battle ag…

The Director-General of the World Health Organization (WHO), Dr Tedros Adhanom Ghebreyesus, met President Xi Jinping of the People's Republic of China in Beijing. They sh...

Bayer and Nuvisan create new research unit in Berl…

Bayer AG today announced that it entered into a definitive agreement to transfer a large part of its Berlin-based small molecule research unit to Nuvisan, an internationa...

FDA approves first drug for treatment of peanut al…

Today the U.S. Food and Drug Administration approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to mitigate allergic reactions, including anaphylaxis, tha...

Can bilingualism protect the brain even with early…

A study by York University psychology researchers provides new evidence that bilingualism can delay symptoms of dementia. Alzheimer's disease is the most common form of d...

Poliovirus therapy shows potential as cancer vacci…

A modified form of poliovirus, pioneered at Duke Cancer Institute as a therapy for glioblastoma brain tumors, appears in laboratory studies to also have applicability for...